Condition: Usher Syndrome, Type 1B · Sponsor: AAVantgarde Bio Srl
The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.
This description comes directly from the study's public registry record.
Clinical Operations Manager · +448000465680 · clinicaltrials@aavantgarde.com
Always discuss trial participation with your own doctor first.
| University of Campania Luigi Vanvitelli | Naples, Italy | Recruiting |
| Moorfields Eye Hospital | London, United Kingdom | Recruiting |
| Retina Clinic London | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06591793